{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:32:46Z","timestamp":1788197566408,"version":"build-2803163510"},"reference-count":163,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T00:00:00Z","timestamp":1337126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Med"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.2119\/molmed.2011.00196","type":"journal-article","created":{"date-parts":[[2012,10,3]],"date-time":"2012-10-03T14:34:56Z","timestamp":1349274896000},"page":"957-970","source":"Crossref","is-referenced-by-count":142,"title":["Expanding the Clinical Indications for \u03b11-Antitrypsin Therapy"],"prefix":"10.1186","volume":"18","author":[{"given":"Eli C","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,16]]},"reference":[{"key":"1806657_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0378-4320(03)00169-6","volume":"79","author":"H Niemann","year":"2003","unstructured":"Niemann H, Kues WA. (2003) Application of transgenesis in livestock for agriculture and biomedicine. Anim. Reprod. Sci. 79:291\u2013317.","journal-title":"Anim. Reprod. Sci."},{"key":"1806657_CR2","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1164\/rccm.201108-1428CI","volume":"185","author":"JK Stoller","year":"2012","unstructured":"Stoller JK, Aboussouan LS. (2012) A review of alpha1-antitrypsin deficiency. Am. J. Respir. Crit. Care Med. 185:246\u201359.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1806657_CR3","first-page":"1678","volume":"116","author":"Z Jie","year":"2003","unstructured":"Jie Z, et al. (2003) Protective effects of alpha 1-antitrypsin on acute lung injury in rabbits induced by endotoxin. Chin. Med. J. 116:1678\u201382.","journal-title":"Chin. Med. J."},{"key":"1806657_CR4","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1189\/jlb.0208145","volume":"85","author":"GB Pott","year":"2009","unstructured":"Pott GB, Chan ED, Dinarello CA, Shapiro L. (2009) Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J. Leukoc. Biol. 85:886\u201395.","journal-title":"J. Leukoc. Biol."},{"key":"1806657_CR5","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1084\/jem.178.5.1629","volume":"178","author":"H Tilg","year":"1993","unstructured":"Tilg H, Vannier E, Vachino G, Dinarello CA, Mier JW. (1993) Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J. Exp. Med. 178:1629\u201336.","journal-title":"J. Exp. Med."},{"key":"1806657_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11011-011-9239-9","volume":"26","author":"S Subramanian","year":"2011","unstructured":"Subramanian S, et al. (2011) Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice. Metab. Brain Dis. 26:107\u201313.","journal-title":"Metab. Brain Dis."},{"key":"1806657_CR7","doi-asserted-by":"publisher","first-page":"16242","DOI":"10.1073\/pnas.0808031105","volume":"105","author":"M Koulmanda","year":"2008","unstructured":"Koulmanda M, et al. (2008) Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc. Natl. Acad. Sci. U. S. A. 105:16242\u20137.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1806657_CR8","doi-asserted-by":"publisher","first-page":"16236","DOI":"10.1073\/pnas.0807627105","volume":"105","author":"EC Lewis","year":"2008","unstructured":"Lewis EC, et al. (2008) Alpha1-antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc. Natl. Acad. Sci. U. S. A. 105:16236\u201341.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1806657_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.4049\/jimmunol.1101340","volume":"189","author":"E Ozeri","year":"2012","unstructured":"Ozeri E, Mizrahi M, Shahaf G, Lewis EC. (2012) \u03b1-1 Antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells. J. Immunol. 189:146\u201353.","journal-title":"J. Immunol."},{"key":"1806657_CR10","doi-asserted-by":"publisher","first-page":"12153","DOI":"10.1073\/pnas.0505579102","volume":"102","author":"EC Lewis","year":"2005","unstructured":"Lewis EC, Shapiro L, Bowers OJ, Dinarello CA. (2005) Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc. Natl. Acad. Sci. U. S. A. 102:12153\u20138.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1806657_CR11","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1182\/blood-2011-07-365247","volume":"118","author":"AM Marcondes","year":"2011","unstructured":"Marcondes AM, et al. (2011) Inhibition of IL-32 activation by alpha-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model. Blood. 118:5031\u20139.","journal-title":"Blood"},{"key":"1806657_CR12","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1073\/pnas.1117665109","volume":"109","author":"I Tawara","year":"2012","unstructured":"Tawara I, et al. (2012) Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc. Natl. Acad. Sci. U. S. A. 109:564\u20139.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1806657_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/274589a0","volume":"274","author":"PK Arora","year":"1978","unstructured":"Arora PK, Miller HC, Aronson LD. (1978) Alpha1-antitrypsin is an effector of immunological stasis. Nature. 274:589\u201390.","journal-title":"Nature"},{"key":"1806657_CR14","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1056\/NEJM198704233161704","volume":"316","author":"MD Wewers","year":"1987","unstructured":"Wewers MD, et al. (1987) Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N. Engl. J. Med. 316:1055\u201362.","journal-title":"N. Engl. J. Med."},{"key":"1806657_CR15","first-page":"A4175","volume":"57","author":"PC Gotzsche","year":"2010","unstructured":"Gotzsche PC, Johansen HK. (2010) Intravenous alpha-1 antitrypsin augmentation therapy: systematic review. Dan. Med. Bull. 57:A4175.","journal-title":"Dan. Med. Bull."},{"key":"1806657_CR16","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.rmed.2011.02.002","volume":"105","author":"SM Janciauskiene","year":"2011","unstructured":"Janciauskiene SM, et al. (2011) The discovery of alpha1-antitrypsin and its role in health and disease. Respir. Med. 105:1129\u201339.","journal-title":"Respir. Med."},{"key":"1806657_CR17","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1080\/00016340802428146","volume":"87","author":"A Larsson","year":"2008","unstructured":"Larsson A, Palm M, Hansson LO, Basu S, Axelsson O. (2008) Reference values for alpha1-acid glycoprotein, alpha1-antitrypsin, albumin, haptoglobin, C-reactive protein, IgA, IgG and IgM during pregnancy. Acta. Obstet. Gynecol. Scand. 87:1084\u20138.","journal-title":"Acta. Obstet. Gynecol. Scand."},{"key":"1806657_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1093\/ageing\/afn039","volume":"37","author":"L Paczek","year":"2008","unstructured":"Paczek L, Michalska W, Bartlomiejczyk I. (2008) Trypsin, elastase, plasmin and MMP-9 activity in the serum during the human ageing process. Age Ageing. 37:318\u201323.","journal-title":"Age Ageing."},{"key":"1806657_CR19","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s001090050364","volume":"77","author":"R Dhami","year":"1999","unstructured":"Dhami R, et al. (1999) Pulmonary epithelial expression of human alpha1-antitrypsin in transgenic mice results in delivery of alpha1-antitrypsin protein to the interstitium. J. Mol. Med. (Berl.). 77:377\u201385.","journal-title":"J. Mol. Med. (Berl.)"},{"key":"1806657_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1513\/pats.201002-020AW","volume":"7","author":"RM Tuder","year":"2010","unstructured":"Tuder RM, Janciauskiene SM, Petrache I. (2010) Lung disease associated with alpha1-antitrypsin deficiency. Proc. Am. Thorac. Soc. 7:381\u20136.","journal-title":"Proc. Am. Thorac. Soc."},{"key":"1806657_CR21","first-page":"184","volume":"67","author":"FJ Serres de","year":"2007","unstructured":"de Serres FJ, Blanco I, Fernandez-Bustillo E. (2007) PI S and PI Z alpha-1 antitrypsin deficiency worldwide: a review of existing genetic epidemiological data. Monaldi Arch. Chest Dis. 67:184\u2013208.","journal-title":"Monaldi Arch. Chest Dis."},{"key":"1806657_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1146\/annurev-med-042409-151920","volume":"62","author":"DH Perlmutter","year":"2011","unstructured":"Perlmutter DH. (2011) Alpha-1-antitrypsin deficiency: importance of proteasomal and autophagic degradative pathways in disposal of liver disease-associated protein aggregates. Annu. Rev. Med. 62:333\u201345.","journal-title":"Annu. Rev. Med."},{"key":"1806657_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3109\/01902148.2011.554599","volume":"37","author":"D Wang","year":"2011","unstructured":"Wang D, et al. (2011) Deletion of Serpina1a, a murine alpha1-antitrypsin ortholog, results in embryonic lethality. Exp. Lung Res. 37:291\u2013300.","journal-title":"Exp. Lung Res."},{"key":"1806657_CR24","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1164\/ajrccm.164.5.2103040","volume":"164","author":"WL Lee","year":"2001","unstructured":"Lee WL, Downey GP. (2001) Leukocyte elastase: physiological functions and role in acute lung injury. Am. J. Respir. Crit. Care Med. 164:896\u2013904.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1806657_CR25","doi-asserted-by":"crossref","first-page":"16713","DOI":"10.1016\/S0021-9258(17)44815-0","volume":"265","author":"DH Perlmutter","year":"1990","unstructured":"Perlmutter DH, et al. (1990) Endocytosis and degradation of alpha 1-antitrypsin-protease complexes is mediated by the serpin-enzyme complex (SEC) receptor. J. Biol. Chem. 265:16713\u20136.","journal-title":"J. Biol. Chem."},{"key":"1806657_CR26","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1016\/S0021-9258(18)99160-X","volume":"266","author":"G Joslin","year":"1991","unstructured":"Joslin G, Fallon RJ, Bullock J, Adams SP, Perlmutter DH. (1991) The SEC receptor recognizes a pentapeptide neodomain of alpha 1-antitrypsin-protease complexes. J. Biol. Chem. 266:11282\u20138.","journal-title":"J. Biol. Chem."},{"key":"1806657_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.bbrc.2004.01.055","volume":"315","author":"S Janciauskiene","year":"2004","unstructured":"Janciauskiene S, Zelvyte I, Jansson L, Stevens T. (2004) Divergent effects of alpha1-antitrypsin on neutrophil activation, in vitro. Biochem. Biophys. Res. Commun. 315:288\u201396.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1806657_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0021-9150(00)00767-X","volume":"158","author":"S Janciauskiene","year":"2001","unstructured":"Janciauskiene S, Moraga F, Lindgren S. (2001) C-terminal fragment of alpha1-antitrypsin activates human monocytes to a pro-inflammatory state through interactions with the CD36 scavenger receptor and LDL receptor. Atherosclerosis. 158:41\u201351.","journal-title":"Atherosclerosis"},{"key":"1806657_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.biocel.2005.09.021","volume":"38","author":"D Subramaniyam","year":"2006","unstructured":"Subramaniyam D, et al. (2006) C-36 peptide, a degradation product of alpha1-antitrypsin, modulates human monocyte activation through LPS signaling pathways. Int. J. Biochem. Cell Biol. 38:563\u201375.","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"1806657_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0021-9150(99)00194-X","volume":"147","author":"S Janciauskiene","year":"1999","unstructured":"Janciauskiene S, Wright HT, Lindgren S. (1999) Atherogenic properties of human monocytes induced by the carboxyl terminal proteolytic fragment of alpha-1-antitrypsin. Atherosclerosis. 147:263\u201375.","journal-title":"Atherosclerosis"},{"key":"1806657_CR31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1006\/mcbr.2000.0256","volume":"4","author":"W Dichtl","year":"2000","unstructured":"Dichtl W, et al. (2000) The carboxyl-terminal fragment of alpha1-antitrypsin is present in atherosclerotic plaques and regulates inflammatory transcription factors in primary human mono-cytes. Mol. Cell. Biol. Res. Commun. 4:50\u201361.","journal-title":"Mol. Cell. Biol. Res. Commun."},{"key":"1806657_CR32","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1189\/jlb.0108001","volume":"83","author":"V Shpacovitch","year":"2008","unstructured":"Shpacovitch V, Feld M, Hollenberg MD, Luger TA, Steinhoff M. (2008) Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J. Leukoc. Biol. 83:1309\u201322.","journal-title":"J. Leukoc. Biol."},{"key":"1806657_CR33","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0002-9440(10)64316-7","volume":"162","author":"RC Fields","year":"2003","unstructured":"Fields RC, et al. (2003) Protease-activated receptor-2 signaling triggers dendritic cell development. Am. J. Pathol. 162:1817\u201322.","journal-title":"Am. J. Pathol."},{"key":"1806657_CR34","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ahj.2008.09.025","volume":"157","author":"R Shah","year":"2009","unstructured":"Shah R. (2009) Protease-activated receptors in cardiovascular health and diseases. Am. Heart J. 157:253\u201362.","journal-title":"Am. Heart J."},{"key":"1806657_CR35","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1172\/JCI21689R1","volume":"116","author":"N Vergnolle","year":"2006","unstructured":"Vergnolle N, et al. (2006) A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J. Clin. Invest. 116:2056.","journal-title":"J. Clin. Invest."},{"key":"1806657_CR36","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1084\/jem.20052148","volume":"203","author":"F Noorbakhsh","year":"2006","unstructured":"Noorbakhsh F, et al. (2006) Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J. Exp. Med. 203:425\u201335.","journal-title":"J. Exp. Med."},{"key":"1806657_CR37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.bbagen.2005.06.009","volume":"1725","author":"K Yoshida","year":"2005","unstructured":"Yoshida K, et al. (2005) Aggrecanase-1 (ADAMTS\u20134) interacts with alpha1-antitrypsin. Biochim. Biophys. Acta. 1725:152\u20139.","journal-title":"Biochim. Biophys. Acta."},{"key":"1806657_CR38","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0092-8674(00)00087-8","volume":"102","author":"Z Liu","year":"2000","unstructured":"Liu Z, et al. (2000) The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B\/MMP-9 in vivo. Cell. 102:647\u201355.","journal-title":"Cell"},{"key":"1806657_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/138920108783497631","volume":"9","author":"ME Muroski","year":"2008","unstructured":"Muroski ME, et al. (2008) Matrix metalloproteinase-9\/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Curr. Pharm. Biotechnol. 9:34\u201346.","journal-title":"Curr. Pharm. Biotechnol."},{"key":"1806657_CR40","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2119\/molmed.2011.00089","volume":"17","author":"M Al-Omari","year":"2011","unstructured":"Al-Omari M, et al. (2011) Acute-phase protein alpha1-antitrypsin inhibits neutrophil calpain I and induces random migration. Mol. Med. 17:865\u201374.","journal-title":"Mol. Med."},{"key":"1806657_CR41","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1189\/jlb.0910538","volume":"89","author":"GB Segel","year":"2011","unstructured":"Segel GB, Halterman MW, Lichtman MA. (2011) The paradox of the neutrophil\u2019s role in tissue injury. J. Leukoc. Biol. 89:359\u201372.","journal-title":"J. Leukoc. Biol."},{"key":"1806657_CR42","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1172\/JCI41196","volume":"120","author":"DA Bergin","year":"2010","unstructured":"Bergin DA, et al. (2010) Alpha-1 antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J. Clin. Invest. 120:4236\u201350.","journal-title":"J. Clin. Invest."},{"key":"1806657_CR43","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/978-1-4614-1680-7_9","volume":"738","author":"Y Miyake","year":"2012","unstructured":"Miyake Y, Yamasaki S. (2012) Sensing necrotic cells. Adv. Exp. Med. Biol. 738:144\u201352.","journal-title":"Adv. Exp. Med. Biol."},{"key":"1806657_CR44","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1189\/jlb.0810471","volume":"89","author":"MF Tsan","year":"2011","unstructured":"Tsan MF. (2011) Heat shock proteins and high mobility group box 1 protein lack cytokine function. J. Leukoc. Biol. 89:847\u201353.","journal-title":"J. Leukoc. Biol."},{"key":"1806657_CR45","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.bbrc.2004.01.058","volume":"315","author":"P Finotti","year":"2004","unstructured":"Finotti P, Pagetta A. (2004) A heat shock protein70 fusion protein with alpha1-antitrypsin in plasma of type 1 diabetic subjects. Biochem. Biophys. Res. Commun. 315:297\u2013305.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1806657_CR46","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.biocel.2010.06.009","volume":"42","author":"D Subramaniyam","year":"2010","unstructured":"Subramaniyam D, et al. (2010) Cholesterol rich lipid raft microdomains are gateway for acute phase protein, SERPINA1. Int. J. Biochem. Cell Biol. 42:1562\u201370.","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"1806657_CR47","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2174\/187152508785909537","volume":"6","author":"M Correale","year":"2008","unstructured":"Correale M, Brunetti ND, De Gennaro L, Di Biase M. (2008) Acute phase proteins in atherosclerosis (acute coronary syndrome). Cardiovasc. Hematol. Agents Med. Chem. 6:272\u20137.","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"1806657_CR48","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1161\/hq1101.098232","volume":"21","author":"S Mashiba","year":"2001","unstructured":"Mashiba S, et al. (2001) In vivo complex formation of oxidized alpha(1)-antitrypsin and LDL. Arterioscler. Thromb. Vasc. Biol. 21:1801\u20138.","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1806657_CR49","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1161\/01.ATV.0000065196.61663.8D","volume":"23","author":"PJ Talmud","year":"2003","unstructured":"Talmud PJ, et al. (2003) Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arterioscler. Thromb. Vasc. Biol. 23:644\u20139.","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1806657_CR50","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1096\/fj.00-0311com","volume":"15","author":"L Shapiro","year":"2001","unstructured":"Shapiro L, Pott GB, Ralston AH. (2001) Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1. FASEB J. 15:115\u201322.","journal-title":"FASEB J."},{"key":"1806657_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.cell.2007.02.042","volume":"129","author":"J Munch","year":"2007","unstructured":"Munch J, et al. (2007) Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell. 129:263\u201375.","journal-title":"Cell"},{"key":"1806657_CR52","doi-asserted-by":"publisher","first-page":"E384","DOI":"10.25011\/cim.v33i6.14589","volume":"33","author":"CL Bryan","year":"2010","unstructured":"Bryan CL, et al. (2010) HIV infection is associated with reduced serum alpha-1-antitrypsin concentrations. Clin. Invest. Med. 33:E384\u20139.","journal-title":"Clin. Invest. Med."},{"key":"1806657_CR53","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bbrc.2006.02.190","volume":"343","author":"LF Congote","year":"2006","unstructured":"Congote LF. (2006) The C-terminal 26-residue peptide of serpin A1 is an inhibitor of HIV-1. Biochem. Biophys. Res. Commun. 343:617\u201322.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1806657_CR54","doi-asserted-by":"publisher","first-page":"63re63","DOI":"10.1126\/scitranslmed.3001697","volume":"2","author":"WG Forssmann","year":"2010","unstructured":"Forssmann WG, et al. (2010) Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide. Sci. Transl. Med. 2:63re63.","journal-title":"Sci. Transl. Med."},{"key":"1806657_CR55","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1164\/rccm.200512-1842OC","volume":"173","author":"I Petrache","year":"2006","unstructured":"Petrache I, et al. (2006) A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am. J. Respir. Crit. Care Med. 173:1222\u20138.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1806657_CR56","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1513\/pats.200605-124SF","volume":"3","author":"RM Tuder","year":"2006","unstructured":"Tuder RM, Yoshida T, Fijalkowka I, Biswal S, Petrache I. (2006) Role of lung maintenance program in the heterogeneity of lung destruction in emphysema. Proc. Am. Thorac. Soc. 3:673\u20139.","journal-title":"Proc. Am. Thorac. Soc."},{"key":"1806657_CR57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1475-2867-4-7","volume":"4","author":"I Zelvyte","year":"2004","unstructured":"Zelvyte I, Stevens T, Westin U, Janciauskiene S. (2004) Alpha1-antitrypsin and its C-terminal fragment attenuate effects of degranulated neutrophil-conditioned medium on lung cancer HCC cells, in vitro. Cancer Cell Int. 4:7.","journal-title":"Cancer Cell Int."},{"key":"1806657_CR58","doi-asserted-by":"publisher","first-page":"L534","DOI":"10.1152\/ajplung.90505.2008","volume":"296","author":"E Kurtagic","year":"2009","unstructured":"Kurtagic E, Jedrychowski MP, Nugent MA. (2009) Neutrophil elastase cleaves VEGF to generate a VEGF fragment with altered activity. Am. J. Physiol. Lung Cell Mol. Physiol. 296:L534\u201346.","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1806657_CR59","doi-asserted-by":"publisher","first-page":"12799","DOI":"10.1074\/jbc.275.17.12799","volume":"275","author":"Y Ikari","year":"2000","unstructured":"Ikari Y, Fujikawa K, Yee KO, Schwartz SM. (2000) Alpha(1)-proteinase inhibitor, alpha(1)-antichymotrypsin, or alpha(2)-macroglobulin is required for vascular smooth muscle cell spreading in three-dimensional fibrin gel. J. Biol. Chem. 275:12799\u2013805.","journal-title":"J. Biol. Chem."},{"key":"1806657_CR60","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2353\/ajpath.2006.060058","volume":"169","author":"I Petrache","year":"2006","unstructured":"Petrache I, et al. (2006) Alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am. J. Pathol. 169:1155\u201366.","journal-title":"Am. J. Pathol."},{"key":"1806657_CR61","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1165\/rcmb.2002-0228OC","volume":"29","author":"RM Tuder","year":"2003","unstructured":"Tuder RM, et al. (2003) Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am. J. Respir. Cell Mol. Biol. 29:88\u201397.","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1806657_CR62","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1513\/pats.200603-068MS","volume":"3","author":"JA Elias","year":"2006","unstructured":"Elias JA, Kang MJ, Crothers K, Homer R, Lee CG. (2006) State of the art: mechanistic heterogeneity in chronic obstructive pulmonary disease: insights from transgenic mice. Proc. Am. Thorac. Soc. 3:494\u20138.","journal-title":"Proc. Am. Thorac. Soc."},{"key":"1806657_CR63","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1164\/ajrccm.163.3.2002117","volume":"163","author":"Y Kasahara","year":"2001","unstructured":"Kasahara Y, et al. (2001) Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am. J. Respir. Crit. Care Med. 163:737\u201344.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1806657_CR64","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1096\/fj.00-0343com","volume":"15","author":"L Taraseviciene-Stewart","year":"2001","unstructured":"Taraseviciene-Stewart L, et al. (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 15:427\u201338.","journal-title":"FASEB J."},{"key":"1806657_CR65","doi-asserted-by":"publisher","first-page":"27865","DOI":"10.1074\/jbc.270.46.27865","volume":"270","author":"RH Wenger","year":"1995","unstructured":"Wenger RH, Rolfs A, Marti HH, Bauer C, Gassmann M. (1995) Hypoxia, a novel inducer of acute phase gene expression in a human hepatoma cell line. J. Biol. Chem. 270:27865\u201370.","journal-title":"J. Biol. Chem."},{"key":"1806657_CR66","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1378\/chest.125.5.1607","volume":"125","author":"MD Wewers","year":"2004","unstructured":"Wewers MD. (2004) Alpha1-antitrypsin deficiency: more than a protease imbalance? Chest. 125:1607\u20139.","journal-title":"Chest"},{"key":"1806657_CR67","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1002\/eji.200737296","volume":"37","author":"X Zhong","year":"2007","unstructured":"Zhong X, et al. (2007) Reciprocal generation of Th1\/Th17 and T(reg) cells by B1 and B2 B cells. Eur. J. Immunol. 37:2400\u20134.","journal-title":"Eur. J. Immunol."},{"key":"1806657_CR68","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2009-08-236521","volume":"115","author":"WW Lee","year":"2010","unstructured":"Lee WW, et al. (2010) Regulating human Th17 cells via differential expression of IL-1 receptor. Blood. 115:530\u201340.","journal-title":"Blood"},{"key":"1806657_CR69","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/15412550600651248","volume":"3","author":"PA Pemberton","year":"2006","unstructured":"Pemberton PA, et al. (2006) Inhaled recombinant alpha 1-antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. COPD. 3:101\u20138.","journal-title":"COPD"},{"key":"1806657_CR70","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.imlet.2005.08.006","volume":"102","author":"R Hadzic","year":"2006","unstructured":"Hadzic R, et al. (2006) Alpha1-antitrypsin inhibits Moraxella catarrhalis MID protein-induced tonsillar B cell proliferation and IL-6 release. Immunol. Lett. 102:141\u20137.","journal-title":"Immunol. Lett."},{"key":"1806657_CR71","first-page":"105","volume":"72","author":"CA Blank","year":"1994","unstructured":"Blank CA, Brantly M. (1994) Clinical features and molecular characteristics of alpha 1-antitrypsin deficiency. Ann. Allergy. 72:105\u201320.","journal-title":"Ann. Allergy."},{"key":"1806657_CR72","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.diabres.2009.03.003","volume":"84","author":"M Yaghmaei","year":"2009","unstructured":"Yaghmaei M, et al. (2009) Serum trypsin inhibitory capacity in normal pregnancy and gestational diabetes mellitus. Diabetes Res. Clin. Pract. 84:201\u20134.","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1806657_CR73","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1586\/eci.10.95","volume":"7","author":"UI Ekeowa","year":"2011","unstructured":"Ekeowa UI, Marciniak SJ, Lomas DA. (2011) Alpha(1)-antitrypsin deficiency and inflammation. Expert Rev. Clin. Immunol. 7:243\u201352.","journal-title":"Expert Rev. Clin. Immunol."},{"key":"1806657_CR74","doi-asserted-by":"crossref","unstructured":"Schmechel DE, Edwards CL. (2012) Fibromyalgia, mood disorders, and intense creative energy: A1AT polymorphisms are not always silent. Neurotoxicology. 2012 March 10 [Epub ahead of print]","DOI":"10.1016\/j.neuro.2012.03.001"},{"key":"1806657_CR75","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.neuro.2007.05.011","volume":"28","author":"DE Schmechel","year":"2007","unstructured":"Schmechel DE. (2007) Art, alpha-1-antitrypsin polymorphisms and intense creative energy: blessing or curse? Neurotoxicology. 28:899\u2013914.","journal-title":"Neurotoxicology"},{"key":"1806657_CR76","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.cell.2010.02.043","volume":"140","author":"CA Dinarello","year":"2010","unstructured":"Dinarello CA. (2010) Anti-inflammatory agents: present and future. Cell. 140:935\u201350.","journal-title":"Cell"},{"key":"1806657_CR77","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1358\/dot.2010.46.11.1534820","volume":"46","author":"CV Desouza","year":"2010","unstructured":"Desouza CV. (2010) An overview of salsalate as a potential antidiabetic therapy. Drugs Today (Barc.). 46:847\u201353.","journal-title":"Drugs Today (Barc.)"},{"key":"1806657_CR78","first-page":"3868","volume":"169","author":"CM Larsen","year":"2007","unstructured":"Larsen CM, et al. (2007) [Interleukin-1 receptor antagonist-treatment of patients with type 2 diabetes]. Ugeskr. Laeger. 169:3868\u201371.","journal-title":"Ugeskr. Laeger."},{"key":"1806657_CR79","first-page":"755","volume":"12","author":"J Geiler","year":"2010","unstructured":"Geiler J, McDermott MF. (2010) Gevokizumab, an anti-IL-1beta mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr. Opin. Mol. Ther. 12:755\u201369.","journal-title":"Curr. Opin. Mol. Ther."},{"key":"1806657_CR80","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","volume":"11","author":"MY Donath","year":"2011","unstructured":"Donath MY, Shoelson SE. (2011) Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11:98\u2013107.","journal-title":"Nat. Rev. Immunol."},{"key":"1806657_CR81","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1126\/science.3086977","volume":"232","author":"K Bendtzen","year":"1986","unstructured":"Bendtzen K, et al. (1986) Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science. 232:1545\u20137.","journal-title":"Science"},{"key":"1806657_CR82","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4161\/isl.2.3.11654","volume":"2","author":"M Kalis","year":"2010","unstructured":"Kalis M, Kumar R, Janciauskiene S, Salehi A, Cilio CM. (2010) Alpha 1-antitrypsin enhances insulin secretion and prevents cytokine-mediated apoptosis in pancreatic beta-cells. Islets. 2:185\u20139.","journal-title":"Islets"},{"key":"1806657_CR83","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11892-009-0018-5","volume":"9","author":"GC Weir","year":"2009","unstructured":"Weir GC, Koulamnda M. (2009) Control of inflammation with alpha1-antitrypsin: a potential treatment for islet transplantation and new-onset type 1 diabetes. Curr. Diab. Rep. 9:100\u20132.","journal-title":"Curr. Diab. Rep."},{"key":"1806657_CR84","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.transproceed.2008.02.010","volume":"40","author":"A Pileggi","year":"2008","unstructured":"Pileggi A, et al. (2008) Alpha-1 antitrypsin treatment of spontaneously diabetic nonobese diabetic mice receiving islet allografts. Transplant Proc. 40:457\u20138.","journal-title":"Transplant Proc."},{"key":"1806657_CR85","doi-asserted-by":"publisher","first-page":"12651","DOI":"10.1073\/pnas.0506079102","volume":"102","author":"TB Strom","year":"2005","unstructured":"Strom TB. (2005) Saving islets from allograft rejection. Proc. Natl. Acad. Sci. U. S. A. 102:12651\u20132.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1806657_CR86","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/jcb.10114","volume":"85","author":"G Papaccio","year":"2002","unstructured":"Papaccio G, Pedulla M, Ammendola E, Todaro M. (2002) Cytokine regulatory effects on alpha-1 proteinase inhibitor expression in NOD mouse islet endothelial cells. J. Cell. Biochem. 85:123\u201330.","journal-title":"J. Cell. Biochem."},{"key":"1806657_CR87","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/j.1464-5491.2008.02584.x","volume":"25","author":"CS Sandstrom","year":"2008","unstructured":"Sandstrom CS, et al. (2008) An association between type 2 diabetes and alpha-antitrypsin deficiency. Diabet. Med. 25:1370\u20133.","journal-title":"Diabet. Med."},{"key":"1806657_CR88","doi-asserted-by":"crossref","unstructured":"Phillips B, Trucco M, Giannoukakis N. (2011) Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same? Clin. Dev. Immunol. 2011:432016.","DOI":"10.1155\/2011\/432016"},{"key":"1806657_CR89","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/ncpendmet0783","volume":"4","author":"MY Donath","year":"2008","unstructured":"Donath MY, Mandrup-Poulsen T. (2008) The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus. Nat. Clin. Pract. Endocrinol. Metab. 4:240\u20131.","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"1806657_CR90","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/j.1399-5448.2011.00761.x","volume":"12","author":"KM Sumpter","year":"2011","unstructured":"Sumpter KM, Adhikari S, Grishman EK, White PC. (2011) Preliminary studies related to anti-interleukin-1beta therapy in children with newly diagnosed type 1 diabetes. Pediatr. Diabetes. 12:656\u201367.","journal-title":"Pediatr. Diabetes."},{"key":"1806657_CR91","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.diabres.2006.06.020","volume":"75","author":"M Hashemi","year":"2007","unstructured":"Hashemi M, Naderi M, Rashidi H, Ghavami S. (2007) Impaired activity of serum alpha-1-antitrypsin in diabetes mellitus. Diabetes Res. Clin. Pract. 75:246\u20138.","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1806657_CR92","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s00592-006-0220-8","volume":"43","author":"B Lisowska-Myjak","year":"2006","unstructured":"Lisowska-Myjak B, Pachecka J, Kaczynska B, Miszkurka G, Kadziela K. (2006) Serum protease inhibitor concentrations and total antitrypsin activity in diabetic and non-diabetic children during adolescence. Acta Diabetol. 43:88\u201392.","journal-title":"Acta Diabetol."},{"key":"1806657_CR93","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1006\/clin.1998.4605","volume":"89","author":"CL Bristow","year":"1998","unstructured":"Bristow CL, Di Meo F, Arnold RR. (1998) Specific activity of alpha1proteinase inhibitor and alpha2macroglobulin in human serum: application to insulin-dependent diabetes mellitus. Clin. Immunol. Immunopathol. 89:247\u201359.","journal-title":"Clin. Immunol. Immunopathol."},{"key":"1806657_CR94","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0168-8227(88)80059-7","volume":"5","author":"M Sandler","year":"1988","unstructured":"Sandler M, Gemperli BM, Hanekom C, Kuhn SH. (1988) Serum alpha 1-protease inhibitor in diabetes mellitus: reduced concentration and impaired activity. Diabetes Res. Clin. Pract. 5:249\u201355.","journal-title":"Diabetes Res. Clin. Pract."},{"key":"1806657_CR95","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0009-8981(86)90335-9","volume":"160","author":"P Hall","year":"1986","unstructured":"Hall P, Tryon E, Nikolai TF, Roberts RC. (1986) Functional activities and nonenzymatic glycosylation of plasma proteinase inhibitors in diabetes. Clin. Chim. Acta. 160:55\u201362.","journal-title":"Clin. Chim. Acta."},{"key":"1806657_CR96","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1089\/hum.2006.17.625","volume":"17","author":"Y Lu","year":"2006","unstructured":"Lu Y, et al. (2006) Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice. Hum. Gene Ther. 17:625\u201334.","journal-title":"Hum. Gene Ther."},{"key":"1806657_CR97","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1007\/s00125-010-1829-2","volume":"53","author":"H Ma","year":"2010","unstructured":"Ma H, et al. (2010) Intradermal alpha1-antitrypsin therapy avoids fatal anaphylaxis, prevents type 1 diabetes and reverses hypergly-caemia in the NOD mouse model of the disease. Diabetologia. 53:2198\u2013204.","journal-title":"Diabetologia"},{"key":"1806657_CR98","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2337\/db06-1273","volume":"56","author":"B Zhang","year":"2007","unstructured":"Zhang B, et al. (2007) Alpha1-antitrypsin protects beta-cells from apoptosis. Diabetes. 56:1316\u201323.","journal-title":"Diabetes"},{"key":"1806657_CR99","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.2337\/diabetes.48.9.1773","volume":"48","author":"J Lou","year":"1999","unstructured":"Lou J, et al. (1999) Expression of alpha-1 proteinase inhibitor in human islet microvascular endothelial cells. Diabetes. 48:1773\u20138.","journal-title":"Diabetes"},{"key":"1806657_CR100","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1007\/s00125-005-1816-1","volume":"48","author":"D Bosco","year":"2005","unstructured":"Bosco D, et al. (2005) Expression and secretion of alpha1-proteinase inhibitor are regulated by proinflammatory cytokines in human pancreatic islet cells. Diabetologia. 48:1523\u201333.","journal-title":"Diabetologia"},{"key":"1806657_CR101","first-page":"RA19","volume":"13","author":"M Fujita","year":"2007","unstructured":"Fujita M, Nakanishi Y. (2007) The pathogenesis of COPD: lessons learned from in vivo animal models. Med. Sci. Monit. 13:RA19\u201324.","journal-title":"Med. Sci. Monit."},{"key":"1806657_CR102","doi-asserted-by":"crossref","unstructured":"Pizzutto SJ, Upham JW, Yerkovich ST, Chang AB. (2010) Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis. Cochrane Database Syst. Rev. CD007525.","DOI":"10.1002\/14651858.CD007525.pub2"},{"key":"1806657_CR103","first-page":"A1185","volume":"179","author":"E Kerem","year":"2009","unstructured":"Kerem E, et al. (2009) Safety and efficacy of inhaled human alpha-1 antitrypsin (AAT) in cystic fibrosis (CF): a report of a phase II clinical study [abstract]. Am. J. Respir. Crit. Care Med. 179:A1185.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1806657_CR104","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1164\/rccm.200901-0069OC","volume":"180","author":"PD Sly","year":"2009","unstructured":"Sly PD, et al. (2009) Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am. J. Respir. Crit. Care Med. 180:146\u201352.","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"Suppl.2","key":"1806657_CR105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/2047-783X-15-S2-164","volume":"15","author":"R Siekmeier","year":"2010","unstructured":"Siekmeier R. (2010) Lung deposition of inhaled alpha-1-proteinase inhibitor (alpha 1-PI): problems and experience of alpha1-PI inhalation therapy in patients with hereditary alpha1-PI deficiency and cystic fibrosis. Eur. J. Med. Res. 15 (Suppl. 2):164\u201374.","journal-title":"Eur. J. Med. Res."},{"key":"1806657_CR106","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1399-3046.2011.01553.x","volume":"15","author":"LE Hagen","year":"2011","unstructured":"Hagen LE, et al. (2011) High alpha-1 antitrypsin clearance predicts severity of gut graft-versus-host disease (GVHD) in children. Pediatr. Transplant. 15:659\u201363.","journal-title":"Pediatr. Transplant."},{"key":"1806657_CR107","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA. (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 117:3720\u201332.","journal-title":"Blood"},{"key":"1806657_CR108","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1182\/blood.V84.4.1342.1342","volume":"84","author":"JH Antin","year":"1994","unstructured":"Antin JH, et al. (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood. 84:1342\u20138.","journal-title":"Blood"},{"key":"1806657_CR109","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1182\/blood-2002-03-0985","volume":"100","author":"JH Antin","year":"2002","unstructured":"Antin JH, et al. (2002) Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood. 100:3479\u201382.","journal-title":"Blood"},{"key":"1806657_CR110","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00109-011-0767-x","volume":"89","author":"R Zeiser","year":"2011","unstructured":"Zeiser R, Penack O, Holler E, Idzko M. (2011) Danger signals activating innate immunity in graft-versus-host disease. J. Mol. Med. (Berl.). 89:833\u201345.","journal-title":"J. Mol. Med. (Berl.)"},{"key":"1806657_CR111","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1136\/ard.2010.134684","volume":"69","author":"IB McInnes","year":"2010","unstructured":"McInnes IB, O\u2019Dell JR. (2010) State-of-the-art: rheumatoid arthritis. Ann. Rheum. Dis. 69:1898\u2013906.","journal-title":"Ann. Rheum. Dis."},{"key":"1806657_CR112","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/art.1780371203","volume":"37","author":"K Chidwick","year":"1994","unstructured":"Chidwick K, et al. (1994) Relationship between alpha 1-antitrypsin inactivation and tumor necrosis factor alpha concentration in the synovial fluid of patients with rheumatoid arthritis. Arthritis Rheum. 37:1723\u20136.","journal-title":"Arthritis Rheum."},{"key":"1806657_CR113","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1006\/cimm.1995.1183","volume":"165","author":"K Kakimoto","year":"1995","unstructured":"Kakimoto K, Matsukawa A, Yoshinaga M, Nakamura H. (1995) Suppressive effect of a neutrophil elastase inhibitor on the development of collagen-induced arthritis. Cell Immunol. 165:26\u201332.","journal-title":"Cell Immunol."},{"key":"1806657_CR114","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1479-5876-9-21","volume":"9","author":"C Grimstein","year":"2011","unstructured":"Grimstein C, et al. (2011) Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model. J. Transi. Med. 9:21.","journal-title":"J. Transi. Med."},{"key":"1806657_CR115","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/jgm.1409","volume":"12","author":"C Grimstein","year":"2010","unstructured":"Grimstein C, et al. (2010) Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis. J. Gene Med. 12:35\u201344.","journal-title":"J. Gene Med."},{"key":"1806657_CR116","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1177\/1073858410371379","volume":"16","author":"V Wee Yong","year":"2010","unstructured":"Wee Yong V. (2010) Inflammation in neurological disorders: a help or a hindrance? Neuroscientist. 16:408\u201320.","journal-title":"Neuroscientist"},{"key":"1806657_CR117","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1600-0404.1995.tb07027.x","volume":"91","author":"YI Lolin","year":"1995","unstructured":"Lolin YI, Ward AM. (1995) Alpha-1-antitrypsin phenotypes and associated disease patterns in neurological patients. Acta Neurol. Scand. 91:394\u20138.","journal-title":"Acta Neurol. Scand."},{"key":"1806657_CR118","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ana.410180417","volume":"18","author":"PA McCombe","year":"1985","unstructured":"McCombe PA, et al. (1985) Alpha-1 antitrypsin phenotypes in demyelinating disease: an association between demyelinating disease and the allele PiM3. Ann. Neurol. 18:514\u20136.","journal-title":"Ann. Neurol."},{"key":"1806657_CR119","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/archneur.1985.04210090039011","volume":"42","author":"GS Pearl","year":"1985","unstructured":"Pearl GS, Mullins RE. (1985) Alpha 1-antitrypsin in cerebrospinal fluid of patients with neurologic diseases. Arch. Neurol. 42:775\u20137.","journal-title":"Arch. Neurol."},{"key":"1806657_CR120","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1080\/00365529850166248","volume":"33","author":"C Folwaczny","year":"1998","unstructured":"Folwaczny C, et al. (1998) Alpha1-antitrypsin alleles and phenotypes in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 33:78\u201381.","journal-title":"Scand. J. Gastroenterol."},{"key":"1806657_CR121","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/ibd.20425","volume":"14","author":"R Kotlowski","year":"2008","unstructured":"Kotlowski R, Bernstein CN, Silverberg MS, Krause DO. (2008) Population-based case-control study of alpha 1-antitrypsin and SLC11A1 in Crohn\u2019s disease and ulcerative colitis. Inflamm. Bowel Dis. 14:1112\u20137.","journal-title":"Inflamm. Bowel Dis."},{"key":"1806657_CR122","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1172\/JCI116797","volume":"92","author":"EP Molmenti","year":"1993","unstructured":"Molmenti EP, Perlmutter DH, Rubin DC. (1993) Cell-specific expression of alpha 1-antitrypsin in human intestinal epithelium. J. Clin. Invest. 92:2022\u201334.","journal-title":"J. Clin. Invest."},{"key":"1806657_CR123","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.amjcard.2010.03.032","volume":"106","author":"AT Turer","year":"2010","unstructured":"Turer AT, Hill JA. (2010) Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am. J. Cardiol. 106:360\u20138.","journal-title":"Am. J. Cardiol."},{"key":"1806657_CR124","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s12265-010-9193-7","volume":"3","author":"B Jiang","year":"2010","unstructured":"Jiang B, Liao R. (2010) The paradoxical role of inflammation in cardiac repair and regeneration. J. Cardiovasc. Transl. Res. 3:410\u20136.","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"1806657_CR125","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.yjmcc.2011.05.003","volume":"51","author":"S Toldo","year":"2011","unstructured":"Toldo S, et al. (2011) Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J. Mol. Cell. Cardiol. 51:244\u201351.","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1806657_CR126","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1161\/01.CIR.102.12.1420","volume":"102","author":"MA Daemen","year":"2000","unstructured":"Daemen MA, et al. (2000) Functional protection by acute phase proteins alpha(1)-acid glycoprotein and alpha(1)-antitrypsin against ischemia\/reperfusion injury by preventing apoptosis and inflammation. Circulation. 102:1420\u20136.","journal-title":"Circulation"},{"key":"1806657_CR127","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/0002-9378(86)90343-1","volume":"155","author":"N Kanayama","year":"1986","unstructured":"Kanayama N, Kamijo H, Terao T, Horiuchi K, Fujimoto D. (1986) The relationship between trypsin activity in amniotic fluid and premature rupture of membranes. Am. J. Obstet. Gynecol. 155:1043\u20138.","journal-title":"Am. J. Obstet. Gynecol."},{"key":"1806657_CR128","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/molehr\/gan071","volume":"15","author":"N Izumi-Yoneda","year":"2009","unstructured":"Izumi-Yoneda N, et al. (2009) Alpha 1 antitrypsin activity is decreased in human amnion in premature rupture of the fetal membranes. Mol. Hum. Reprod. 15:49\u201357.","journal-title":"Mol. Hum. Reprod."},{"key":"1806657_CR129","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.rmed.2008.10.006","volume":"103","author":"LS Aboussouan","year":"2009","unstructured":"Aboussouan LS, Stoller JK. (2009) Detection of alpha-1 antitrypsin deficiency: a review. Respir. Med. 103:335\u201341.","journal-title":"Respir. Med."},{"key":"1806657_CR130","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1164\/rccm.200302-203OC","volume":"168","author":"A Churg","year":"2003","unstructured":"Churg A, Wang RD, Xie C, Wright JL. (2003) Alpha-1-antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. Am. J. Respir. Crit. Care Med. 168:199\u2013207.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"1806657_CR131","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1378\/chest.118.5.1480","volume":"118","author":"J Lieberman","year":"2000","unstructured":"Lieberman J. (2000) Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest. 118:1480\u20135.","journal-title":"Chest"},{"key":"1806657_CR132","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/ijc.20494","volume":"112","author":"H Huang","year":"2004","unstructured":"Huang H, et al. (2004) Alpha1-antitrypsin inhibits angiogenesis and tumor growth. Int. J. Cancer. 112:1042\u20138.","journal-title":"Int. J. Cancer."},{"key":"1806657_CR133","first-page":"745","volume":"82","author":"J Yavelow","year":"1997","unstructured":"Yavelow J, Tuccillo A, Kadner SS, Katz J, Finlay TH. (1997) Alpha 1-antitrypsin blocks the release of transforming growth factor-alpha from MCF-7 human breast cancer cells. J. Clin. Endocrinol. Metab. 82:745\u201352.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1806657_CR134","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1042\/bst0300111","volume":"30","author":"JM Sallenave","year":"2002","unstructured":"Sallenave JM. (2002) Antimicrobial activity of antiproteinases. Biochem. Soc. Trans. 30:111\u20135.","journal-title":"Biochem. Soc. Trans."},{"key":"1806657_CR135","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1128\/AAC.41.9.2006","volume":"41","author":"JR Forney","year":"1997","unstructured":"Forney JR, Yang S, Healey MC. (1997) Synergistic anticryptosporidial potential of the combination alpha-1-antitrypsin and paromomycin. Antimicrob. Agents Chemother. 41:2006\u20138.","journal-title":"Antimicrob. Agents Chemother."},{"key":"1806657_CR136","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1006\/bbrc.1999.2046","volume":"267","author":"Y Miyamoto","year":"2000","unstructured":"Miyamoto Y, et al. (2000) Novel functions of human alpha(1)-protease inhibitor after S-nitrosylation: inhibition of cysteine protease and antibacterial activity. Biochem. Biophys. Res. Commun. 267:918\u201323.","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1806657_CR137","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1126\/science.1833820","volume":"254","author":"R Porat","year":"1991","unstructured":"Porat R, Clark BD, Wolff SM, Dinarello CA. (1991) Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. Science. 254:430\u20132.","journal-title":"Science"},{"key":"1806657_CR138","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1128\/JCM.25.5.889-892.1987","volume":"25","author":"GR Riveau","year":"1987","unstructured":"Riveau GR, Novitsky TJ, Roslansky PF, Dinarello CA, Warren HS. (1987) Role of interleukin-1 in augmenting serum neutralization of bacterial lipopolysaccharide. J. Clin. Microbiol. 25:889\u201392.","journal-title":"J. Clin. Microbiol."},{"key":"1806657_CR139","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1080\/00365540701225744","volume":"39","author":"ED Chan","year":"2007","unstructured":"Chan ED, et al. (2007) Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages. Scand. J. Infect. Dis. 39:690\u20136.","journal-title":"Scand. J. Infect. Dis."},{"key":"1806657_CR140","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1378\/chest.119.3.737","volume":"119","author":"M Wencker","year":"2001","unstructured":"Wencker M, Fuhrmann B, Banik N, Konietzko N. (2001) Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest. 119:737\u201344.","journal-title":"Chest"},{"key":"1806657_CR141","first-page":"178","volume":"69","author":"I Blanco","year":"2008","unstructured":"Blanco I, et al. (2008) Long-term augmentation therapy with alpha-1 antitrypsin in an MZ-AAT severe persistent asthma. Monaldi Arch. Chest Dis. 69:178\u201382.","journal-title":"Monaldi Arch. Chest Dis."},{"key":"1806657_CR142","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1517\/14656566.8.15.2609","volume":"8","author":"NM Mordwinkin","year":"2007","unstructured":"Mordwinkin NM, Louie SG. (2007) Aralast: an alpha 1-protease inhibitor for the treatment of alpha-antitrypsin deficiency. Expert Opin. Pharmacother. 8:2609\u201314.","journal-title":"Expert Opin. Pharmacother."},{"key":"1806657_CR143","first-page":"193","volume":"3","author":"I Petrache","year":"2009","unstructured":"Petrache I, Hajjar J, Campos M. (2009) Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. Biologics. 3:193\u2013204.","journal-title":"Biologics"},{"key":"1806657_CR144","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1183\/09031936.00047306","volume":"29","author":"M Griese","year":"2007","unstructured":"Griese M, et al. (2007) Alpha1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur. Respir. J. 29:240\u201350.","journal-title":"Eur. Respir. J."},{"key":"1806657_CR145","doi-asserted-by":"publisher","first-page":"8573","DOI":"10.1074\/jbc.M607976200","volume":"282","author":"SM Janciauskiene","year":"2007","unstructured":"Janciauskiene SM, Nita IM, Stevens T. (2007) Alpha1-antitrypsin, old dog, new tricks: alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J. Biol. Chem. 282:8573\u201382.","journal-title":"J. Biol. Chem."},{"key":"1806657_CR146","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1517\/14712598.8.8.1225","volume":"8","author":"D Wouters","year":"2008","unstructured":"Wouters D, Wagenaar-Bos I, van Ham M, Zeerleder S. (2008) C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opin. Biol. Ther. 8:1225\u201340.","journal-title":"Expert Opin. Biol. Ther."},{"key":"1806657_CR147","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1046\/j.1563-2571.2002.02012.x","volume":"29","author":"CH J Wiedermann","year":"2002","unstructured":"Wiedermann Ch J, Romisch J. (2002) The anti-inflammatory actions of antithrombin: a review. Acta Med. Austriaca. 29:89\u201392.","journal-title":"Acta Med. Austriaca."},{"key":"1806657_CR148","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.2119\/molmed.2011.00145","volume":"17","author":"G Shahaf","year":"2011","unstructured":"Shahaf G, et al. (2011) Alpha-1-antitrypsin gene delivery reduces inflammation, increases T-regulatory cell population size and prevents islet allograft rejection. Mol. Med. 17:1000\u201311.","journal-title":"Mol. Med."},{"key":"1806657_CR149","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1517\/14728214.2010.512287","volume":"15","author":"RA Stockley","year":"2010","unstructured":"Stockley RA. (2010) Emerging drugs for alpha-1-antitrypsin deficiency. Expert Opin. Emerg. Drugs. 15:685\u201394.","journal-title":"Expert Opin. Emerg. Drugs."},{"key":"1806657_CR150","doi-asserted-by":"publisher","first-page":"R87","DOI":"10.1093\/hmg\/ddr156","volume":"20","author":"TR Flotte","year":"2011","unstructured":"Flotte TR, Mueller C. (2011) Gene therapy for alpha-1 antitrypsin deficiency. Hum. Mol. Genet. 20:R87\u201392.","journal-title":"Hum. Mol. Genet."},{"key":"1806657_CR151","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1006\/mthe.2001.0429","volume":"4","author":"SM Stoll","year":"2001","unstructured":"Stoll SM, et al. (2001) Epstein-Barr virus\/human vector provides high-level, long-term expression of alpha1-antitrypsin in mice. Mol. Ther. 4:122\u20139.","journal-title":"Mol. Ther."},{"key":"1806657_CR152","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00726-005-0324-4","volume":"30","author":"E Karnaukhova","year":"2006","unstructured":"Karnaukhova E, Ophir Y, Golding B. (2006) Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use. Amino Acids. 30:317\u201332.","journal-title":"Amino Acids."},{"key":"1806657_CR153","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1165\/rcmb.4866","volume":"27","author":"AM Cantin","year":"2002","unstructured":"Cantin AM, Woods DE, Cloutier D, Dufour EK, Leduc R. (2002) Polyethylene glycol conjugation at Cys232 prolongs the half-life of alpha1 proteinase inhibitor. Am. J. Respir. Cell Mol. Biol. 27:659\u201365.","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1806657_CR154","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1042\/bj20020643","volume":"365","author":"HM Zbikowska","year":"2002","unstructured":"Zbikowska HM, et al. (2002) Uromodulin promoter directs high-level expression of biologically active human alpha1-antitrypsin into mouse urine. Biochem. J. 365:7\u201311.","journal-title":"Biochem. J."},{"key":"1806657_CR155","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1042\/bj0010474","volume":"1","author":"SG Hedin","year":"1906","unstructured":"Hedin SG. (1906) Trypsin and antitrypsin. Biochem. J. 1:474\u201383.","journal-title":"Biochem. J."},{"key":"1806657_CR156","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1750-1172-6-14","volume":"6","author":"I Blanco","year":"2011","unstructured":"Blanco I, Lara B, de Serres F. (2011) Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema. Orphanet J. Rare Dis. 6:14.","journal-title":"Orphanet J. Rare Dis."},{"key":"1806657_CR157","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/nri2873","volume":"10","author":"GY Chen","year":"2010","unstructured":"Chen GY, Nunez G. (2010) Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 10:826\u201337.","journal-title":"Nat. Rev. Immunol."},{"key":"1806657_CR158","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1056\/NEJMra0910283","volume":"364","author":"HK Eltzschig","year":"2011","unstructured":"Eltzschig HK, Carmeliet P. (2011) Hypoxia and inflammation. N. Engl. J. Med. 364:656\u201365.","journal-title":"N. Engl. J. Med."},{"key":"1806657_CR159","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/sj.gt.3302156","volume":"11","author":"S Song","year":"2004","unstructured":"Song S, et al. (2004) Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther. 11:181\u20136.","journal-title":"Gene Ther."},{"key":"1806657_CR160","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/j.transproceed.2010.05.119","volume":"42","author":"G Loganathan","year":"2010","unstructured":"Loganathan G, et al. (2010) Culture of impure human islet fractions in the presence of alpha-1 antitrypsin prevents insulin cleavage and improves islet recovery. Transplant. Proc. 42:2055\u20137.","journal-title":"Transplant. Proc."},{"key":"1806657_CR161","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.peptides.2007.10.011","volume":"29","author":"LF Congote","year":"2008","unstructured":"Congote LF, Temmel N, Sadvakassova G, Dobocan MC. (2008) Comparison of the effects of serpin A1, a recombinant serpin A1-IGF chimera and serpin A1 C-terminal peptide on wound healing. Peptides. 29:39\u201346.","journal-title":"Peptides"},{"key":"1806657_CR162","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1465-9921-6-12","volume":"6","author":"I Nita","year":"2005","unstructured":"Nita I, Hollander C, Westin U, Janciauskiene SM. (2005) Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release. Respir. Res. 6:12.","journal-title":"Respir. Res."},{"key":"1806657_CR163","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1002\/bit.23158","volume":"108","author":"V Blanchard","year":"2011","unstructured":"Blanchard V, et al. (2011) N-glycosylation and biological activity of recombinant human alpha1-antitrypsin expressed in a novel human neuronal cell line. Biotechnol. Bioeng. 108:2118\u201328.","journal-title":"Biotechnol. Bioeng."}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2011.00196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.2119\/molmed.2011.00196\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.crossref.org\/molmed.2011.00196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2119\/molmed.2011.00196.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T20:14:27Z","timestamp":1714421667000},"score":1,"resource":{"primary":{"URL":"https:\/\/molmed.biomedcentral.com\/articles\/10.2119\/molmed.2011.00196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,16]]},"references-count":163,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["1806657"],"URL":"https:\/\/doi.org\/10.2119\/molmed.2011.00196","relation":{},"ISSN":["1076-1551","1528-3658"],"issn-type":[{"value":"1076-1551","type":"print"},{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,16]]}}}